Focal Segmental Glomerulosclerosis (FSGS) is the rare kidney disease that affects the filtering system (glomeruli) of kidney, causing severe scarring and renal disease at end stage. For instance, as per the Clinical Journal of American Society of Nephrology, 2017 article, incidence rates of FSGS are often high in men, with around 1.5x higher compared with women. The FSGS is characterized with symptoms including edema, proteinuria, increased cholesterol, weight gain, and proteins within blood.
Global Focal Segmental Glomerulosclerosis Market – Drivers
There are no approved drugs as of now for the FSGS treatment. Hence, limited treatment therapy along with government funding for rare diseases’ research are expected to propel the global focal segmental glomerulosclerosis market growth over the forecast period, as no approved drug is presently available to treat FSGS . For instance, both the U.S. Food and Drug Administration (FDA) along with the European Commission, in 2015, granted Sparsentan, a designation of orphan drug to treat FSGS. The Sparsentan is a new drug candidate having dual action mechanism that combines endothelin receptor blockade with angiotensin receptor blockade and is currently under evaluation of Phase III trial, expected to be over by December 2022.
Rising R&D for drugs of FSGS by several manufacturers is expected to fuel the global focal segmental glomerulosclerosis market growth over the forecast period. For instance, the company Pfizer Inc., is going through clinical trial for its PF-06730512 drug evaluation, in adults having primary FSGS. The drug is presently under study of Phase II and is expected to be finished by June 2021.
Ask for PDF sample copy of the Focal Segmental Glomerulosclerosis market report @ https://www.coherentmarketinsights.com/insight/request-pdf/2224
Furthermore, government investments in the treatment of this rare disease is expected to propel the global focal segmental glomerulosclerosis market growth over the forecast period. For instance, as per the 2017 annual data report by the U.S. Renal Data System, Medicare put in over US$ 34 Bn for patients on dialysis having chronic kidney diseases.
Global Focal Segmental Glomerulosclerosis Market – Restraint
Absence of awareness among the populace regarding the disease along with high dialysis therapy cost is expected to restrict the global focal segmental glomerulosclerosis market growth over the forecast period. For instance, as per the University of Michigan published article in 2017, awareness in patients regarding FSGS is relatively low when patients are in FSGS’s primary stage, this is expected to hamper the global focal segmental glomerulosclerosis market growth over the forecast period.
Global Focal Segmental Glomerulosclerosis Market – Regional Analysis
Based on geography, the global focal segmental glomerulosclerosis market is segregated into North America, Europe, Latin America, Asia Pacific, Africa, and Middle East.
North America is expected to hold a dominant position in the global focal segmental glomerulosclerosis (FSGS) market owing to high FSGS and chronic kidney diseases’ prevalence. For instance, as per the 2017 annual data report from the U.S. Renal Data System, the overall incidence of kidney disease, kidney transplantation, and kidney failure along with dialysis, is highest in the U.S., thereby expected to drive the global focal segmental glomerulosclerosis market growth in this region.
Buy Now this Premium Report to Grow your Business: https://www.coherentmarketinsights.com/insight/buy-now/2224
Asia Pacific is expected to register robust growth in the global focal segmental glomerulosclerosis (FSGS) market owing to partnerships and collaboration agreements among several players. For instance, the Indian company Aten Porus’s subsidiary – Oraxion Therapeutics, Inc., is going through efficacy and preclinical study of the ORX-301 drug, which could be used to treat FSGS. Oraxion Therapeutics, Inc., in February 2018, signed an Option Agreement along with the Biopharmaceutical Company based in U.S. and under the agreement, the company receives exclusive rights for the further license and clinical studies of the drug within the U.S.
Major players functioning in the global focal segmental glomerulosclerosis (FSGS) market are GlaxoSmithKline plc, Variant Pharmaceuticals, Inc., Novartis AG, ChemoCentryx, Inc., AbbVie, Inc., Retrophin, Inc., AstraZeneca plc, Pfizer, Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd., and others.
Global Focal Segmental Glomerulosclerosis Market – Taxonomy
On the basis of Disease Type
- Secondary Focal Segmental Glomerulosclerosis
- Primary Focal Segmental Glomerulosclerosis
On the basis of Drug
- Sparsentan (Phase III)
On the basis of Distribution channels
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
On the basis of region
- North America
- Asia Pacific
- Latin America
- Middle East
Got any Query? Feel free to ask us at: https://www.coherentmarketinsights.com/insight/talk-to-analyst/2224
Table of Content
Global Focal Segmental Glomerulosclerosis Market Research Report
Section 1: Global Focal Segmental Glomerulosclerosis Industry Overview
Section 2: Global Economic Impact on Focal Segmental Glomerulosclerosis Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Focal Segmental Glomerulosclerosis Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Focal Segmental Glomerulosclerosis Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027